Got $1,000? 3 Stocks to Buy Now While They're On Sale

Three consumer growth stocks trading materially below prior highs present actionable opportunities: e.l.f. Beauty (down ~50%) has gained U.S. mass color cosmetics share for 22 consecutive quarters to 12.3% (Q2), is positioned to replicate its color playbook in skincare and expand internationally (just 16% of Q2 sales abroad), and trades at a forward FY2026 P/E of ~26 with a PEG of 0.6. Dutch Bros posted Q2 revenue growth of 30% and 4.1% same‑store sales, operates 912 locations (612 company‑owned) with AUVs near $2.0m, and — despite trimming near‑term openings after refining real‑estate criteria — retains a long national expansion runway while trading at a similar forward price‑to‑sales multiple as Starbucks. Chewy (down ~25%) benefits from a highly recurring model (≈78% auto‑ship sales; ≈85% non‑discretionary), has substantial margin upside from private label (+700bps) and an underpenetrated pet pharmacy (~20% of ~20m customers, pharmacy margins up to +1000bps), and trades at under ~23x forward consensus earnings, making all three compelling ideas for investors seeking consumer growth at discounted valuations.

Analysis

e.l.f. Beauty is down about 50% from its highs despite 22 consecutive quarters of color cosmetics market-share gains and a 12.3% U.S. mass share in Q2; the company generated only 16% of Q2 sales internationally, presenting a clear runway for expansion and adjacent growth into skincare, and it trades at a forward FY2026 P/E of ~26 with a PEG of 0.6. Dutch Bros delivered strong Q2 operating performance—30% revenue growth and 4.1% same-store sales—with 912 locations (612 company-owned) and average unit volumes near $2.0m, but the stock sold off after management trimmed near-term store openings while refining real-estate criteria; the company still has a long national expansion runway and currently trades at a forward price-to-sales multiple similar to Starbucks despite a far smaller footprint. Chewy is about 25% off its highs but retains a highly recurring revenue base (≈78% of last quarter sales from auto-ship; ≈85% of last year’s sales non-discretionary) and identifiable margin levers: private-label SKUs (≈+700bps margin) and a heavily underpenetrated pet pharmacy (≈20m active customers with ~20% pharmacy penetration and pharmacy margins up to +1000bps); management expects sales trends to normalize next year and the name trades under ~23x forward earnings. Market signals show a moderately positive, bullish tone with limited market-impact (sentiment score 0.6, market impact 0.25), suggesting favorable analyst sentiment but that catalysts will be execution-driven rather than macro-driven in the near term.

Key Decisions for Investors

• Consider initiating a modest position in e.l.f. while shares trade ~50% off highs given its 22-quarter share gains, 12.3% U.S. share and a PEG of 0.6, but size allocations conservatively until skincare rollouts and international expansion show concrete sales conversion
• Accumulate Dutch Bros selectively for long-term unit economics and national expansion potential—Q2 revenue +30% and AUVs near $2.0m are supportive—while monitoring the company’s revised store-opening cadence and real-estate execution as near-term risks
• Buy or add to Chewy exposure to capture recurring revenue and outsized margin upside from private label and pharmacy (700–1000bps potential), and treat pharmacy adoption rates and gross-margin expansion as the primary catalysts to increase exposure
• Employ disciplined position sizing and risk controls (staggered entries or protective hedges) and use quarterly KPIs—e.l.f. international/skincare sales, Dutch Bros store-growth guidance and AUVs, and Chewy pharmacy penetration and gross-margin trends—as triggers to add, trim, or hedge positions